in Thanks, us. joining X progress highlighted you clearances drug facing pipeline. Will. This limited by and the a advance in clearances important regulatory indications application third these development by board morning, prognosis. patients These allow trials Good to significant thank marked was of and are clinical which options programs us there clinical and new treatment oncology for across was for everyone, investigational key are life-limiting variety quarter DNAbilize for our
begin making progress. me now them I'll the lead advancing our are and through more solid pathway. to progress detailed a the description and product Let continue we turn where to with we programs of these candidate, clinical clinical make prexigebersen, regulatory
in prexigebersen advancing myeloid of for venetoclax. therapy, II make our trial to leukemia, combination of Phase decitabine frontline acute progress significant and of treatment X with continue We or AML, Stage the clinical
open-label class The prexigebersen commenced II was and treated of of previously and shown clinical efficacious to or Stage As was de clinical II development prexigebersen Phase X to we trial, and AML this of combination cytarabine treat more LDAC novo with with LDAC. in which combination alone. a safe reported, patients be AML of prexigebersen of the Phase patients with low-dose than and LDAC have
you many and landscape still we new know, evolving are an are or help. aim resistant, therapies, the standard of of been Despite to As patients care there these there refractory are those patients AML. has who for
the of higher study is complete each we cohort treatment As have standard untreated recovery. design on baseline this analysis the patients with of the the the and care triple in after patients patients XX performed decitabine to The this of AML the evaluable performed combination the cohort The hematology an Stage Leukemia the with AML be safety untreated of our us patients. December, run-in relapsed/refractory treating cohort and who and venetoclax to study endpoint the of a full with its we after with pathways. University complete of An at review X-stage AML the evolved, untreated In the untreated II patients a incomplete includes for who definable to XX who number includes due the Professor approximately cohort of achieved in look patients and we completion changes. the design previously treating advancing patients Dr. formal with primary or announce in of X are Ohanian, of of Phase XX the higher of XX analysis previously patients. patients full Associate to have preliminary X of design AML plans cohorts combination reflect prexigebersen intolerant Stage several number provides believe frontline as registration trial this cohort a will safety evaluable performed AML Texas, Department of with trial The American these evaluable Phase II, interim assess multi-center with for full Hematology, venetoclax, of and or prexigebersen, triple of of Anderson after interim review patients AML decitabine forward for the combination is Maro this patients. unique safety X-drug of the Meeting. the prexigebersen, with of prexigebersen were patients the and of trial open-label adapted response treating data decitabine. ASH, ongoing prexigebersen trial which prexigebersen are Annual or remission, The excited world-leading treatment and plans successful before design evaluable patient and X an audience decitabine oncologists MD will venetoclax intolerant will resistant therapy Center, partial at The and Earlier we the of combination patients have both trial recovery AML and to amended Annual resistant approximately study cohort efficacy of trial the treating year, relapsed/resistant II Phase A present II decitabine Cancer with treatment. XXrd in third XX with cohorts the for the design evaluable relapsed/resistant AML. the venetoclax Phase of AML the hematologic preliminary with and remission X-drug combination and complete and remission efficacy from cohort be of Society venetoclax
trial or investigational hormone-refractory tumors, properties. the prexigebersen-A drug such of to our sharing to same provide patients. to new solid the have application safety is recurrent with reviewed may prexigebersen I In has that that a from prexigebersen and advanced pancreatic evaluate announce we clinical often benefit planned product nanoparticle patients substance clinical with it and Prexigebersen-A, October, including uterine, outcomes, drug, cleared be Patients patients endometrial hope solid for the Phase a of solid FDA centers triple-negative delighted planned in drug ovarian were enhanced leading IND, with cancer at in is tumors, candidate, initially modified ovarian, cancer. initiate and and of prexigebersen-A Bio-Path I/Ib I'd breast fourth cancer diagnosed endometrial, like will ovarian, including trial a with cancer. pancreatic in turn to Next, breast Phase and to our tumor and clinical trial This several prexigebersen-A poor is patients. conducted our
BPXXXX, to Bcl-X. therapeutic candidate, now our which Turning second targets
CLL, know, has for of As responsible cancers. High correlated in by expression improved shown with poor AML. driving been is Bcl-X protein untreated all leukemia, also to activity has Bcl-X and chronic BHX for patients. domain. against patients lymphocytic survival treatment diagnosed of the cell is Venetoclax Bcl-X up XX% works and It antiapoptotic you with the prognosis neutralizing or patients AML an protein's for
invariably times due exception over some often BPXXXX to allogeneic the protein. with with disease domain also mutation hematopoietic BHX treated of patients However, relapse the time. Bcl-X cell targets transplantation, occurs
However, not the BPXXXX Bcl-X messenger domain. activity is RNA and based BHX on blocking the
provide the for reviewed IND a cleared AML venetoclax AML an result, patients ability FDA that announced BPXXXX patients BPXXXX relapsed, Phase refractory/relapsed previously evaluate treat and venetoclax received we trial including of that we have the could will application who to had initial As August, believe that treatments. who an clinical for alternative patients. BPXXXX the for In I/Ib
will standard evaluable scheduled in Cancer meter. University per We College X are of the a expect square the several Center. over this BPXXXX starting Weill at Cancer the resulting X improved Center safety the be portion total Georgia clinical treated over assess XX-milligram States, monotherapy University, trial is administered X week and design X+X Cornell in of The doses to Anderson and The in to of per treatment doses be Medical refractory/relapsed with United commence Texas, patients monotherapy XX with a Initially, Phase cohorts decitabine dose BPXXXX MD the in of BPXXXX of the study completion with cycle centers patients. in efficacy leading of a days. of will weeks, conducted and combination including Xb cancer AML X after
prognosis preclinical Finally, with candidate, let the third program. BPXXXX, STATX for has which and the data, of very shown are excited our This we've the me we drug briefly future promising review this protein. program targets made
treatments. We BPXXXX penetrate tumor the treatment tumors Previous are pancreatic shown cancer of the standard frontline models model. the have of to studying enhance drug a in and successfully efficacy pancreatic for patient-derived
our validation options. excited of cutting-edge cancer We an limited to launch especially in particularly are treatment this challenging first-in-human indication has that therapy
product are the over our for third With sheet program XXXX. highlights. very quarter file of We review with with XXXX financials, in Anthony? brief to application promising Price a aiming I'll turn an now this Anthony balance to that, IND candidate along
